37,719 Shares in Vera Therapeutics, Inc. $VERA Purchased by Jump Financial LLC

Key Points

• Jump Financial LLC invested $906,000 in Vera Therapeutics, acquiring 37,719 shares during the first quarter, representing approximately 0.06% ownership of the company.
• Vera Therapeutics faces mixed analyst ratings, with a current average target price of $63.00 and various analysts adjusting their price targets significantly.
• In recent insider trading, Director Patrick G. Enright purchased 40,607 shares at $22.35 per share, increasing his ownership stake to approximately $80.38 million.

Jump Financial LLC purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 37,719 shares of the company's stock, valued at approximately $906,000. Jump Financial LLC owned approximately 0.06% of Vera Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Vera Therapeutics by 8.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company's stock worth $114,212,000 after purchasing an additional 377,783 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Vera Therapeutics by 18.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 1,675,367 shares of the company's stock valued at $40,243,000 after buying an additional 260,188 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its holdings in shares of Vera Therapeutics by 31.0% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock valued at $60,785,000 after buying an additional 340,488 shares in the last quarter. Woodline Partners LP grew its position in shares of Vera Therapeutics by 20.1% in the 4th quarter. Woodline Partners LP now owns 1,202,466 shares of the company's stock worth $50,852,000 after buying an additional 201,573 shares during the last quarter. Finally, Integral Health Asset Management LLC raised its stake in shares of Vera Therapeutics by 130.0% during the 4th quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company's stock worth $48,634,000 after acquiring an additional 650,000 shares in the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on VERA. Wolfe Research restated a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday, August 4th. JPMorgan Chase & Co. lowered their price objective on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. HC Wainwright reaffirmed a "buy" rating and set a $85.00 target price (up from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Finally, Cantor Fitzgerald dropped their price target on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Vera Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $63.00.

Vera Therapeutics Stock Performance

NASDAQ:VERA traded down $0.87 during trading hours on Thursday, reaching $22.09. The company had a trading volume of 856,760 shares, compared to its average volume of 1,344,162. The firm has a market cap of $1.41 billion, a PE ratio of -6.16 and a beta of 1.17. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03. The business's 50 day moving average price is $22.19 and its 200-day moving average price is $23.47. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same period last year, the business posted ($0.62) EPS. Research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Insiders Place Their Bets

In other Vera Therapeutics news, Director Patrick G. Enright acquired 209,393 shares of the company's stock in a transaction on Monday, June 23rd. The shares were bought at an average cost of $20.87 per share, with a total value of $4,370,031.91. Following the completion of the acquisition, the director owned 3,569,522 shares in the company, valued at approximately $74,495,924.14. This trade represents a 6.23% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 16.30% of the company's stock.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.